Neridronic Acid

DB11620InvestigationalSmall molecule

Neridronic Acid is a bisphosphonate drug that prevents osteoclastic bone resorption which is used for the prevention and treatment of osteoporosis. A medication used to prevent and treat bone loss (typically caused by osteoporosis).

Formula / weight: C₆H₁₇NO₇P₂ · 277.15 g/mol (avg)
Also known as: Neridronate
Code names: AMBTX-01

Resolves to

Compound

UNII8U27U3RIN4CAS79778-41-9ChEMBLCHEMBL55214ChEBI135145PubChem71237

Structure

InChIKeyPUUSSSIBPPTKTP-UHFFFAOYSA-NSMILESNCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

Targets

P14324FDPS

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

5ContraindicationsEach with its own population and attribute set

4Marketed productsAcross 1 country and 1 labeller

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Neridronic Acid, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account